Summary of findings ‐ 400 mg inhaled mannitol vs 50 mg inhaled mannitol
FVC · adults, children and young people with CF
1 finding from 1 review
- no estimate extracted2 studies · 600 participantsModerate
Findings
What do systematic reviews say?
5 questions · 5 findings · 1 reviews
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 40%Low 2 · 40%Moderate 1 · 20%High 0 · 0%
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
FVC (% predicted) Change from baseline · children and young adults with CF
1 finding from 1 review
- no estimate extracted1 study · 22 participantsLow
Summary of findings ‐ Inhaled mannitol vs dornase alfa
FVC · children and young adults with CF
It is very uncertain whether summary of findings ‐ Inhaled mannitol changes lung function: FVC mL (percentage change from baseline) compared with dornase alfa (very low certainty).
1 finding from 1 review
- MD 0.14231 participantsVery low
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
FVC · adults, children and young people with CF
1 finding from 1 review
- no estimate extracted1261 participantsLow
Summary of findings ‐ Inhaled mannitol plus dornase alfa vs dornase alfa
FVC · children and young adults with CF
It is very uncertain whether summary of findings ‐ Inhaled mannitol plus dornase alfa changes lung function: FVC mL (percentage change from baseline) compared with dornase alfa (very low certainty).
1 finding from 1 review
- no estimate extracted231 participantsVery low